Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension RANGER

This extended access study will assess the long-term safety and tolerability of bardoxolone
methyl in qualified patients with pulmonary hypertension (PH) who previously participated in
controlled clinical studies with bardoxolone methyl.

Qualified patients will receive 10 mg of bardoxolone methyl once daily until the drug is
available through commercial channels or until patient withdrawal, whichever is sooner. Dose
de-escalation (down to 5 mg) is permitted during the study, if indicated clinically.

Inclusion Criteria:

- Treatment-compliant patients who are participating in qualifying ongoing studies and
have completed required End-of-Treatment and/or Follow-up visits in a prior clinical
study with bardoxolone methyl

Exclusion Criteria:

- Participation in other investigational clinical studies involving interventional
products being tested or used in a way different from the approved form or when used
for an unapproved indication;

- Patients who have an ongoing SAE from a clinical study that is assessed by the
investigator as related to bardoxolone methyl;

- Unwilling to practice acceptable methods of birth control (both males who have
partners of childbearing potential and females of childbearing potential) while taking
study drug;

- Women who are pregnant or breastfeeding;

- Patient is, in the opinion of the investigator, unable to comply with the requirements
of the study protocol or is unsuitable for the study for any reason;

- Known hypersensitivity to any component of the study drug